What is Zacks Research’s Estimate for SRPT FY2025 Earnings?

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) – Zacks Research reduced their FY2025 earnings per share (EPS) estimates for shares of Sarepta Therapeutics in a research note issued on Monday, November 24th. Zacks Research analyst Team now anticipates that the biotechnology company will earn ($4.31) per share for the year, down from their prior estimate of ($3.19). The consensus estimate for Sarepta Therapeutics’ current full-year earnings is $2.67 per share. Zacks Research also issued estimates for Sarepta Therapeutics’ Q4 2025 earnings at ($1.93) EPS, Q1 2026 earnings at $0.22 EPS, Q2 2026 earnings at $0.40 EPS, Q3 2026 earnings at $0.56 EPS, FY2026 earnings at $1.76 EPS, Q1 2027 earnings at $0.43 EPS, Q2 2027 earnings at $0.46 EPS, Q3 2027 earnings at $0.69 EPS and FY2027 earnings at $2.10 EPS.

Other equities analysts have also recently issued research reports about the stock. BMO Capital Markets raised shares of Sarepta Therapeutics from a “market perform” rating to an “outperform” rating and set a $50.00 target price on the stock in a research report on Monday, September 22nd. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Sarepta Therapeutics in a research report on Monday. Mizuho raised Sarepta Therapeutics from a “neutral” rating to an “outperform” rating and boosted their price objective for the stock from $19.00 to $26.00 in a research report on Wednesday, November 5th. The Goldman Sachs Group raised their target price on Sarepta Therapeutics to $19.00 and gave the company a “neutral” rating in a research report on Thursday, August 7th. Finally, HC Wainwright reiterated a “sell” rating on shares of Sarepta Therapeutics in a research note on Monday, August 25th. Eight analysts have rated the stock with a Buy rating, fifteen have issued a Hold rating and six have given a Sell rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Hold” and an average price target of $33.75.

Sarepta Therapeutics Stock Up 1.9%

Sarepta Therapeutics stock opened at $21.34 on Thursday. Sarepta Therapeutics has a fifty-two week low of $10.41 and a fifty-two week high of $138.81. The stock has a market cap of $2.24 billion, a PE ratio of -24.53 and a beta of 0.52. The firm’s 50-day simple moving average is $20.47 and its 200 day simple moving average is $22.22. The company has a debt-to-equity ratio of 0.84, a quick ratio of 1.81 and a current ratio of 2.89.

Sarepta Therapeutics (NASDAQ:SRPT) last posted its earnings results on Monday, November 3rd. The biotechnology company reported ($0.13) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.02 by ($0.15). The firm had revenue of $399.36 million during the quarter, compared to the consensus estimate of $331.51 million. Sarepta Therapeutics had a negative return on equity of 1.03% and a negative net margin of 2.34%.The business’s revenue was down 14.5% compared to the same quarter last year. During the same quarter in the previous year, the company earned $0.62 EPS.

Institutional Trading of Sarepta Therapeutics

Hedge funds and other institutional investors have recently modified their holdings of the business. iSAM Funds UK Ltd bought a new position in Sarepta Therapeutics in the 3rd quarter worth approximately $25,000. Ancora Advisors LLC lifted its position in shares of Sarepta Therapeutics by 200.0% during the third quarter. Ancora Advisors LLC now owns 1,500 shares of the biotechnology company’s stock worth $29,000 after acquiring an additional 1,000 shares in the last quarter. Byrne Asset Management LLC bought a new position in shares of Sarepta Therapeutics in the third quarter worth $33,000. Parallel Advisors LLC boosted its holdings in shares of Sarepta Therapeutics by 165.3% in the third quarter. Parallel Advisors LLC now owns 2,016 shares of the biotechnology company’s stock worth $39,000 after acquiring an additional 1,256 shares during the period. Finally, Banque Transatlantique SA purchased a new position in shares of Sarepta Therapeutics in the first quarter valued at $44,000. Institutional investors own 86.68% of the company’s stock.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.